Skip to main content

Table 1 Characteristics of patients at baseline and after LEF treatment

From: Leflunomide therapy for IgA vasculitis with nephritis in children

Patient # Gender Age Body weight Prior Mp therapy Organ involvement ISKDC grade LEF treatment duration Follow-up duration Outcome
1 Female 12 years 55 kg 1.45 mg/kg/day, 12 days
2.18 mg/kg/day, 7 days
S, A, K II 8 months 12 months No skin rash
UP: 8 mg/kg/day
2 Male 12 years 45 kg 1.78 mg/kg/day, 3 days
3.56 mg/kg/day, 8 days
11.11 mg/kg/day, 3 days
S, K IIIb 7 months 8 months No skin rash
UP: undetectable
3 Female 11 years 35 kg 2.29 mg/kg/day, 5 days
4.57 mg/kg/day, 6 days
S, K, J IIIb 12 months 18 months No skin rash
UP: undetectable
4 Female 11 years 30 kg 2.67 mg/kg/day, 6 days
5.33 mg/kg/day, 5 days
16.67 mg/kg/day, 3 days
S, K, J IIIa 6 months 32 months No skin rash
UP: undetectable
5 Male 12 years 45 kg 1.78 mg/kg/day, 4 days
3.56 mg/kg/day, 8 days
S, K II 6 months 7 months No skin rash
UP: undetectable
  1. A abdomen, ISKDC International Study of Kidney Disease in Children, K kidney, LEF leflunomide, Mp methylprednisolone, S skin, UP urine protein, J joint